MedTrace Logo

Azathioprine Linked With Impaired Intestinal Epithelial Postoperative Regeneration in Crohn's Disease

NCT05456776 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2022-07-13

No results posted yet for this study

Summary

What is known?

* the impact of AZA, immunomodulatory drug widely used in active CD, on the intestinal wall differs from those of steroids, what is reflected in the significant difference in the postoperative anastomotic leaks rate
* AZA inhibits intestinal epithelial cell growth by inducing the apoptosis and inhibiting proliferation of intestinal epithelial cells in in vitro studies What is new?
* The effect of AZA on cellular damage was assessed in humans' study
* AZA increases cell apoptosis in the intestinal epithelium of active CD patients, much stronger than steroids
* AZA actively promotes the DNA damage repair in the intestinal epithelium; the steroid effect, even when combined with AZA, is not so pronounced
* The intensity of proliferative processes, in contrast to steroids, is significantly inhibited in response to AZA
* The disintegration of the mucosa layer in response to AZA is observed
* The difference in the mechanisms of action of AZA and steroids on the intestinal mucosa may be directly related to the reported difference in the risk of septic postoperative complications, but this requires further research

Conditions

  • Inflammatory Bowel Diseases

Sponsors & Collaborators

  • Centre of Postgraduate Medical Education

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-12-31
Completion
2019-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05456776 on ClinicalTrials.gov